By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bavarian Nordic A/S 

Vesterbrogade 149

Copenhagen    DK-1620  Denmark
Phone: 45-3326-8383 Fax: 45-3326-8380




Company News
Bavarian Nordic (BAVA.CO) Announces Initiation Of NCI-Sponsored Phase 2 Study Of PROSTVAC In Patients With Localized Prostate Cancer 7/24/2015 10:10:25 AM
Bavarian Nordic (BAVA.CO) Announces That The Oxford Vaccines Group Has Initiated A Phase II Study Of The Ebola Prime-Boost Vaccine Regimen Combining MVA-BN Filo And Janssen's Advac Technology 7/15/2015 9:10:09 AM
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015 9:36:46 AM
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015 9:16:12 AM
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/4/2015 5:34:00 AM
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015 10:09:16 AM
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology 1/6/2015 8:53:04 AM
Bavarian Nordic (BAVA.CO) Reaches Enrollment Target In The Pivotal Phase 3 Study Of PROSTVAC® In Prostate Cancer 12/10/2014 8:33:53 AM
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Bavarian Nordic (BAVA.CO) Accelerates Ebola Vaccine Development Programs In Collaboration With The NIH 9/4/2014 8:58:11 AM